The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Individuals meeting criteria for treatment-resistant depression (TRD) are differentially affected by high levels of anxiety symptoms. Aims: There is a need to identify the efficacy of novel rapid-onset treatments in adults with mood disorders and comorbid anxious-distress. Methods: This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic.Anxious-distress was proxied using items from the Quick Inventory of Depressive Symptomatology–Self Report 16-item (QIDS-SR 16 ) and Generalized Anxiety Disorder 7-item (GAD7) scales. The difference in QIDS-SR 16 total score, QIDS-SR 16 suicidal ideation (SI) item and GAD7 score were analyzed between groups. Results: A total of 209 adults with MDD ( n = 177) and BD ( n = 26) were included in this analysis. From this sample, 94 patients (mean = 45 ± 13.9 years) met the criteria for anxious-distress. Individuals meeting the criteria for anxious-distress exhibited a significantly greater reduction in QIDS-SR 16 total score following four infusions ( p = 0.02) when compared with patients not meeting the anxious-distress criteria. Both anxious-distressed and low-anxiety patients exhibited a significant reduction in SI ( p < 0.0001) following four infusions.Finally, there was a significantly greater reduction in anxiety symptoms in the anxious-distress group compared with the non–anxious distress group following three ( p = 0.02) and four infusions ( p < 0.001). Conclusion: Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study found that repeated ketamine infusions significantly reduced measures of suicidality in an outpatient cohort of 177 participants with MDD and 26 participants with BD [86].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [86]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
The REDCap consortium: building an international community of software platform partners
Harris, P. A., Taylor, R., Minor, B. L., Elliott, V., Fernandez, M., O'Neal, L., McLeod, L., Delacqua, G., Delacqua, F., Kirby, J., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103208 · Cited by 24,013
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
(1997) · PubMed · Cited by 727
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Comorbid depression and anxiety spectrum disorders
Gorman, J. M. (1996) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1996)4:4<160::aid-da2>3.0.co;2-j · Cited by 630
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418 · cited 9×
“The CRTCE is a multidisciplinary center focused on treating adult patients (age ⩾ 18 years) with TRD, defined as having at least two inadequate prior antidepressant treatments (i.e. stage 2 resistance defined by Thase and Rush (1997)).”
BackgroundInfluentialRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279 · cited 9×
“The CRTCE is a multidisciplinary center focused on treating adult patients (age ⩾ 18 years) with TRD, defined as having at least two inadequate prior antidepressant treatments (i.e. stage 2 resistance defined by Thase and Rush (1997)).”
BackgroundInfluentialAnxiety sensitivity and suicidal ideation/suicide risk: A meta-analysis.
Stanley, I. H., Boffa, J. W., Rogers, M. L., Hom, M. A., Albanese, B. J., Chu, C., Capron, D. W., Schmidt, N. B., & Joiner, T. E. (2018) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000342 · Cited by 180
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162
Albott, C. S., Lim, K. O., Forbes, M. K., Erbes, C., Tye, S. J., Grabowski, J. G., Thuras, P., Batres-y-Carr, T. M., Wels, J., & Shiroma, P. R. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11634 · Cited by 159
McIntyre, R. S., Rodrigues, N. B., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L. M. W., Senyk, O., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.088 · Cited by 110 · cited 1×
“This report is a post hoc analysis of data previously described elsewhere (McIntyre et al., 2020).”
MethodSelf-citationA single infusion of ketamine improves depression scores in patients with anxious bipolar depression
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. (2015) · Bipolar Disorders · doi:10.1111/bdi.12277 · Cited by 104
Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118762073 · Cited by 100
Frye, M. A., Blier, P., & Tye, S. J. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000316 · Cited by 75
Falk, E., Schlieper, D., van Caster, P., Lutterbeck, M. J., Schwartz, J., Cordes, J., Grau, I., Kienbaum, P., & Neukirchen, M. (2020) · BMC Palliative Care · doi:10.1186/s12904-019-0499-1 · Cited by 57 · cited 1×
“It has also been reported that IV ketamine and its enantiomer esketamine are able to significantly reduce severe anxiety symptoms after a single infusion (Falk et al., 2020; Ionescu et al., 2015; Salloum et al., 2019).”
BackgroundSalloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoeppner, B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2019) · Depression and Anxiety · doi:10.1002/da.22875 · Cited by 50
Lorenzo-Luaces, L., Zimmerman, M., & Cuijpers, P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.066 · Cited by 42
Weiss, S. J., Simeonova, D. I., Kimmel, M., Battle, C. L., Maki, P. M., & Flynn, H. A. (2015) · Archives of Women s Mental Health · doi:10.1007/s00737-015-0575-3 · Cited by 40
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc128 · Cited by 38
Association between depression subtypes and response to repeated‐dose intravenous ketamine
Wang, C., Zhou, Y., Zheng, W., Liu, W., Zhan, Y., Li, H., Chen, L., Zhang, B., Walter, M., Li, M., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13096 · Cited by 35
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting
Feifel, D., Malcolm, B., Boggie, D., & Lee, K. C. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.043 · Cited by 34
Cognitive Control Functions in Unipolar Major Depression with and without Co-Morbid Anxiety Disorder
Lyche, P., Jonassen, R., Stiles, T. C., Ulleberg, P., & Landrø, N. I. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00149 · Cited by 33
Bandelow, B., Bauer, M., Vieta, E., El-Khalili, N., Gustafsson, U., Earley, W. R., & Eriksson, H. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.842654 · Cited by 18
Research works printed but not linked: 2
- CADTH, 2014, Intravenous Ketamine for the Treatment of Mental Health Disorders: A Review of Clinical Effectiveness and Guidelines
- Thase ME, 1997, J Clin Psychiatry, 58, 23
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Ketamine treatment for refractory anxiety: A systematic review
Tully, J. L., Dahlén, A. D., Haggarty, C. J., Schiöth, H. B., & Brooks, S. J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15374 · Cited by 104
Martinotti, G., Dell’Osso, B. M., Lorenzo, G. D., Maina, G., Bertolino, A., Clerici, M., Barlati, S., Rosso, G., Nicola, M. D., Marcatili, M., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13296 · Cited by 93
Self-citationd’Andrea, G., Pettorruso, M., Lorenzo, G. D., Mancusi, G., McIntyre, R. S., & Martinotti, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.010 · Cited by 49
Self-citation
Metadata
- Authors
- McIntyre, R. S., Rodrigues, N. B., Lipsitz, O., Nasri, F., Gill, H., Lui, L. M., Subramaniapillai, M., Kratiuk, K., Teopiz, K., Ho, R., Lee, Y., Mansur, R. B., & Rosenblat, J. D.
- Affiliations
- University Health Network (CA)
- Canadian Rapid Treatment Center of Excellence, Mississauga, Canada
- National University of Singapore (SG)
- Corresponding author
- McIntyre, Roger S
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-10-11
- Volume
- 35
- Issue
- 2
- Pages
- 128-136
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3092018809
- Cited by
- 20
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 4 · 2021: 4
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- intravenous ketamine, treatment-resistant depression, bipolar disorder, anxious distress, anxiety comorbidity, suicidal ideation, depressive symptoms, mood disorders
- MeSH terms
- Adult, Anxiety, Anxiety Disorders, Bipolar Disorder, Canada, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Self Report, Suicidal Ideation, Depressive Disorder, Treatment-Resistant, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.